4 not yet recruiting, 4 recruiting, 2 active not recruiting, 1 completed. 7 Phase 2, 3 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 3, Recruiting 3, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 2, Not yet recruiting 1 |
| Not applicable | 2 | Enrolling by invitation 1, Recruiting 1 |
Follow Maintenance Therapy: new trials by email Literature Review of Maintenance Therapy trials Research Report on Maintenance Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy - Squamous Cell Carcinoma of the Anal Canal | Phase 2 | Not yet recruiting | Wang Xin | 34 | 2026-09-20 | 2026-09-08 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia VDCLP+V, 2VIP, Consolidation Therapy - Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2026-04-08 | 2026-08-10 |
| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer maintenance therapy plus lubiprostone, maintenance therapy - Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 124 | 2026-02-24 | 2026-02-12 |
| Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial Induction Therapy, Maintenance Therapy - Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2025-09-04 | 2025-12-18 |
| Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer Stereotactic Body Radiotherapy (SBRT) with maintenance therapy, Maintenance therapy - Pancreatic Cancer Non-resectable | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 24 | 2025-08-14 | 2026-05-20 |
| CNCMT：a Multi-center, Prospective, Single-arm Study Neoadjuvant Chemotherapy (NACT), maintenance therapy - Locally Advanced Cervical Cancer, PD1 | Not applicable | Enrolling by invitation | Hubei Cancer Hospital | 20 | 2024-10-08 | 2026-09-18 |
| CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL P regimen, Course A1 + Vin, Course B1 +Vin - Pediatric Anaplastic Large Cell Lymphoma | Phase 3 | Active not recruiting | Children's Cancer Group, China | 172 | 2021-03-01 | 2026-03-19 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Niraparib - Ovarian Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Recruiting | Shanghai Gynecologic Oncology Group | 167 | 2019-10-18 | 2022-03-18 |
| LBL-2016 for Children or Adolescents in China Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, 6-mercaptopurine,Methotrexate, Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine - Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | Children's Cancer Group, China | 150 | 2016-01-01 | 2026-03-18 |
| Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma induction phase1, induction phase2, protocol M - Lymphoma, Lymphoblastic | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2015-03-01 | 2023-06-18 |
| Long-term Use of Romidepsin in Patients With CTCL Romidepsin - Cutaneous T-cell Lymphoma | Completed | Northwestern University | 47 | 2015-01-01 | 2016-03-11 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Myeloid, Acute (2) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Uterine Cervical Neoplasms (1)
Institute of Hematology & Blood Diseases Hospital, China (3) · Children's Cancer Group, China (2) · Sun Yat-sen University (2) · Hubei Cancer Hospital (1) · Medical College of Wisconsin (1) · Northwestern University (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Gynecologic Oncology Group (1) · Wang Xin (1)
China (9) · United States (2)
Hua Wang, MD. (1) · Joan Guitart, MD (1) · Rongyu Zang, M.D., Ph.D. (1) · Sameem Abedin, MD (1) · Shuhua Yi, Dr (1) · Tingyan Shi, M.D., Ph.D. (1) · Yi-Jin Gao, M.D. (1) · Yijin Gao, MD (1)
PMID 10627444, PMID 16421426, PMID 17003366, PMID 19139435, PMID 19433688, PMID 20679620, PMID 23389497, PMID 24344215, PMID 24475787, PMID 26887549, PMID 28273702, PMID 28787259, PMID 32319233, PMID 32661576, PMID 32730187, PMID 32987765, PMID 35478711